Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Companyâ€™s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	US$16.99	+0.18%	12,923
26-08-13	US$16.96	+2.23%	74,312
26-08-12	US$16.59	+1.28%	17,665
26-08-11	US$16.38	-1.38%	8,780
26-08-10	US$16.61	+2.78%	23,319

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

16.99

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
16.99 ^USD	+0.18%		+5.14%	+209.54%

08-06	Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell Microcap Value Benchmark Index	CI

Market Cap	90.23M 77.93M 73.23M 66.6M 125M 8.63B 127M 858M 335M 4.32B 339M 331M 14.36B	P/E 2026 *	-3.69x	P/E 2027 *	-4.72x
Enterprise Value	90.23M 77.93M 73.23M 66.6M 125M 8.63B 127M 858M 335M 4.32B 339M 331M 14.36B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	88.66%	Yield 2026 *	-	Yield 2027 *	-

08-06	Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell Microcap Value Benchmark Index	CI
06-29	Rallybio Corporation(NasdaqCM:RLYB) added to Russell Microcap Index	CI
06-28	Rallybio Corporation(NasdaqCM:RLYB) added to Russell 3000E Value Benchmark	CI
06-28	Rallybio Corporation(NasdaqCM:RLYB) added to Russell 3000E Index	CI
06-01	Rallybio Corporation, Avenzo Therapeutics, Inc. - M&A Call
06-01	Rallybio Agrees to Acquire Avenzo Therapeutics	MT
06-01	Rallybio Corporation and Avenzo Therapeutics announce merger agreement to advance next-generation oncology therapies and $215 million concurrent private placement	RE
05-31	Avenzo Therapeutics, Inc. entered into a definitive agreement to acquire Rallybio Corporation in a reverse merger transaction.	CI
05-13	Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Rallybio Corp - Candid terminates merger agreement with Rallybio on May 3, 2026 - SEC filing	RE
05-02	Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation in a reverse merger transaction.	CI
03-31	Rallybio Corporation Announces Departure of Steven Ryder as Chief Medical Officer, Effective March 31, 2026	CI

25-04-14	Evercore ISI Downgrades Rallybio to In Line From Outperform	MT
25-04-09	HC Wainwright Downgrades Rallybio to Neutral From Buy	MT
24-05-15	JPMorgan Downgrades Rallybio to Neutral From Overweight	MT
24-04-11	Wedbush Lowers Rallybio's PT to $11 From $13 After Private Placement, Adjusts Full-Year 2024 Share Count; Maintains Outperform Rating	MT
24-03-13	HC Wainwright Cuts Rallybio Price Target to $9 From $12, Maintains Buy Rating	MT

Rallybio Corporation Stock

Stocks

RLYB

US75120L2097

Biotechnology & Medical Research

Valuation: Rallybio Corporation

Chart: Rallybio Corporation

Latest news : Rallybio Corporation

Last Transcript: Rallybio Corporation

Analysts' recommendations: Rallybio Corporation

Press Releases: Rallybio Corporation

News in other languages: Rallybio Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Rallybio Corporation

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-02	Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB	BU
06-01	RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders	BU
06-01	Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement	BU
03-18	BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rallybio Corporation (Nasdaq – RLYB), SunOpta Inc. (Nasdaq – STKL), Talkspace, Inc. (Nasdaq - TALK), Kennedy-Wilson Holdings, Inc. (Nasdaq - KW)	AQ
03-04	Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB	BU

24-04-11	Aktien New York: Dow erholt sich vor Start in die Berichtssaison
24-04-11	Aktien New York: Dow schwächer vor Start in die Berichtssaison
24-04-11	Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet

1 day	+0.18%
1 week	+5.14%
Current month	+6.65%
1 month	+5.33%
3 months	+18.81%
6 months	+252.49%
Current year	+209.54%

1 week	16.23	17.35
1 month	15.85	17.35
Current year	3.67	17.57
1 year	3.67	17.57
3 years	1.76	47.68
5 years	1.76	168
10 years	1.76	206.24

Manager	Title	Age	Since
Stephen Uden CEO	Chief Executive Officer	68	2023-07-31
Jonathan Lieber DFI	Director of Finance/CFO	56	2023-01-31
Melissa Haskell CTO	Chief Tech/Sci/R&D Officer	-	2023-01-31

Director	Title	Age	Since
Martin MacKay CHM	Chairman	69	2017-12-31
Stephen Uden BRD	Director/Board Member	68	2023-07-31
Helen Boudreau BRD	Director/Board Member	60	2020-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/6/26	Helen Boudreau	Fiscal year	Director	7,124	0.1344%
2/18/26	Jonathan Lieber	Free	Chief Financial Officer	3,289	0.0078%
2/18/26	Martin MacKay	Free	Founder	18,055	0.0427%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RALLYBIO CORPORATION	+0.18%	+5.14%	+251.61%	-64.55%	90.23M
LONZA GROUP AG	-1.78%	-1.68%	+1.48%	+15.31%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+563.55%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+71.41%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+8.73%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+49.65%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+118.09%	16.15B
EUROFINS SCIENTIFIC SE	+0.49%	+0.92%	+4.11%	+23.67%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+33.31%	13.37B
Average	-0.58%	+0.95%	+97.30%	+91.02%	26.32B
Weighted average by Cap.	-0.91%	+0.59%	+95.89%	+132.88%

	2026 *	2027 *
Net sales	-	-
Net income	-25.6M -22.11M -20.78M -18.9M -35.53M -2.45B -36.11M -243M -95.19M -1.23B -96.12M -94.03M -4.07B	-26.5M -22.89M -21.51M -19.56M -36.77M -2.53B -37.38M -252M -98.53M -1.27B -99.49M -97.33M -4.22B
Net Debt	-	-